Highlights
- Market Cap
- $7.74B
- Enterprise Value
- $7.24B
- EPS (TTM)
- $6.86
- PE Ratio
- 37.64
- PEG Ratio
- 0.09
- Total Revenue (TTM)
- $389.13M
- EBITDA (TTM)
- $161.30M
- Year Range
- $122.80 - $298.30
- Target Price
- $289.60
- ROA (TTM)
- 15.36%
- ROE (TTM)
- 16.80%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Krystal Biotech, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Krystal Biotech, Inc. (KRYS) has returned 4.78% so far this year and 43.27% over the past 12 months.
Krystal Biotech, Inc.
- 1D
- 4.61%
- 1M
- -6.28%
- YTD
- 4.78%
- 6M
- 46.33%
- 1Y
- 43.27%
- 3Y*
- 47.77%
- 5Y*
- 27.48%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 20, 2017, KRYS's average daily return is +0.24%, while the average monthly return is +4.16%. At this rate, your investment would double in approximately 1.4 years.
Historically, 54% of months were positive and 46% were negative. The best month was Nov 2021 with a return of +60.8%, while the worst month was May 2025 at -25.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, KRYS closed higher 51% of trading days. The best single day was Nov 29, 2021 with a return of +121.7%, while the worst single day was Mar 12, 2020 at -22.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.26% | -1.29% | -6.28% | 4.78% | |||||||||
| 2025 | 1.97% | 12.21% | 0.59% | -5.78% | -25.85% | 9.13% | 11.94% | -4.01% | 19.52% | 11.88% | 10.37% | 13.09% | 57.37% |
| 2024 | -10.33% | 43.34% | 11.58% | -13.94% | 4.53% | 14.74% | 13.52% | -6.40% | -6.71% | -5.22% | 14.43% | -20.65% | 26.28% |
| 2023 | 4.92% | -1.46% | -2.26% | 4.92% | 40.30% | -0.38% | 9.97% | -3.58% | -6.81% | 0.75% | -10.82% | 19.03% | 56.60% |
| 2022 | -15.65% | 7.71% | 4.70% | -8.91% | -2.85% | 11.51% | 10.54% | -3.40% | -0.58% | 9.76% | 1.62% | 1.90% | 13.25% |
| 2021 | 16.17% | 13.19% | -2.35% | 3.12% | -17.88% | 4.23% | -14.06% | -0.86% | -9.89% | -4.06% | 60.81% | -13.16% | 16.58% |
Benchmark Metrics
Krystal Biotech, Inc. has an annualized alpha of 56.40%, beta of 1.27, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 21, 2017.
- This stock captured 170.84% of S&P 500 Index gains but only 40.62% of its losses — a favorable profile for investors.
- R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 56.40%
- Beta
- 1.27
- R²
- 0.11
- Upside Capture
- 170.84%
- Downside Capture
- 40.62%
Return for Risk
Risk / Return Rank
KRYS ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and compare them to a chosen benchmark (S&P 500 Index).
| KRYS | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.02 | 0.90 | +0.12 |
Sortino ratioReturn per unit of downside risk | 1.49 | 1.39 | +0.10 |
Omega ratioGain probability vs. loss probability | 1.20 | 1.21 | -0.01 |
Calmar ratioReturn relative to maximum drawdown | 1.27 | 1.40 | -0.13 |
Martin ratioReturn relative to average drawdown | 2.77 | 6.61 | -3.83 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore KRYS risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Krystal Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Krystal Biotech, Inc. was 53.42%, occurring on Nov 26, 2021. Recovery took 1 trading session.
The current Krystal Biotech, Inc. drawdown is 11.51%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -53.42% | Mar 2, 2021 | 189 | Nov 26, 2021 | 1 | Nov 29, 2021 | 190 |
| -46.65% | Feb 13, 2020 | 24 | Mar 18, 2020 | 205 | Jan 8, 2021 | 229 |
| -44.55% | Nov 30, 2021 | 113 | May 11, 2022 | 231 | Apr 13, 2023 | 344 |
| -42.26% | Jul 29, 2024 | 209 | May 28, 2025 | 125 | Nov 24, 2025 | 334 |
| -35.34% | Jul 23, 2019 | 50 | Oct 1, 2019 | 31 | Nov 13, 2019 | 81 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Krystal Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Krystal Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for KRYS, comparing it with other companies in the Biotechnology industry. Currently, KRYS has a P/E ratio of 37.6. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for KRYS compared to other companies in the Biotechnology industry. KRYS currently has a PEG ratio of 0.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KRYS relative to other companies in the Biotechnology industry. Currently, KRYS has a P/S ratio of 19.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KRYS in comparison with other companies in the Biotechnology industry. Currently, KRYS has a P/B value of 6.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |